Evidence map›Paper›PMID 16371154›Full record

Trial reportBMC infectious diseases2005

A randomised controlled trial of the effects of albendazole in pregnancy on maternal responses to mycobacterial antigens and infant responses to Bacille Calmette-Guérin (BCG) immunisation [ISRCTN32849447].

Alison M Elliott, Proscovia B Namujju, Patrice A Mawa, Maria A Quigley, Margaret Nampijja, Peter M Nkurunziza, John T Belisle, Moses Muwanga, James A G Whitworth, Mother and Baby study team

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC infectious diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Anthelminthic treatment during pregnancy is associated with increased risk of infantile eczema: randomised-controlled trial results.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2011
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. A life without worms.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Alison M ElliottUganda Virus Research Institute, PO Box 49, Entebbe, Uganda. alison.tom@infocom.co.ug
Proscovia B Namujju
Patrice A Mawa
Maria A Quigley
Margaret Nampijja
Peter M Nkurunziza
John T Belisle
Moses Muwanga
James A G Whitworth
Mother and Baby study team
Uganda Virus Research Institute · UGLondon School of Hygiene & Tropical Medicine · GBColorado State University · USMinistry of Agriculture, Animal Industry and Fisheries · UG

Funding

TUBERCULOSIS RESEARCH MATERIALSN01AI025147 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI BRENNAN, PATRICK JOSEPH · 1992 to 1997
–
NIAID NIH HHS N01-AI-25147Wellcome Trust 064693
6 · The paper itself

Abstract

backgroundMaternal schistosomiasis and filariasis have been shown to influence infant responses to neonatal bacille Calmette-Guérin (BCG) immunisation but the effects of maternal hookworm, and of de-worming in pregnancy, are unknown.

methodsIn Entebbe, Uganda, we conducted a randomised, double-blind, placebo-controlled trial of a single dose of 400 mg of albendazole in the second trimester of pregnancy. Neonates received BCG. Interferon-gamma (IFN-gamma) and interleukin (IL)-5 responses to a mycobacterial antigen (crude culture filtrate proteins (CFP) of Mycobacterium tuberculosis) were measured in a whole blood assay. We analysed results for binary variables using chi2 tests and logistic regression. We analysed continuous variables using Wilcoxon's tests.

resultsMaternal hookworm was associated with reduced maternal IFN-gamma responses to CFP (adjusted odds ratio for IFN-gamma > median response: 0.14 (95% confidence interval 0.02-0.83, p = 0.021). Conversely, maternal hookworm was associated with subsequent increased IFN-gamma responses in their one-year-old infants (adjusted OR 17.65 (1.20-258.66; p = 0.013)). Maternal albendazole tended to reduce these effects.

conclusionUntreated hookworm infection in pregnancy was associated with reduced maternal IFN-gamma responses to mycobacterial antigens, but increased responses in their infants one year after BCG immunisation. The mechanisms of these effects, and their implications for protective immunity remain, to be determined.

Indexed as

AdultAlbendazoleAnimalsAntigens, BacterialBCG VaccineDouble-Blind MethodFemaleHelminthsHookworm InfectionsHumansInfantInterferon-gammaMycobacterium tuberculosisPregnancyPregnancy Complications, ParasiticAlbendazoleAntigens, BacterialBCG VaccineInterferon-gamma

Identifiers

PMID16371154
PMCPMC1352364
OpenAlexW1526544645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.